STOP-or-NOT trial finds no significant impact on postoperative outcomes for continuing or discontinuing RAS inhibitors in non-cardiac surgery patients.

The STOP-or-NOT trial, conducted among patients requiring major non-cardiac surgery, found that neither continuing nor discontinuing renin-angiotensin system (RAS) inhibitors significantly impacted postoperative outcomes. With both groups experiencing similar rates of all-cause mortality and major postoperative complications, a tailored approach to RASi continuation is recommended, considering individual patient factors, surgery specifics, and patient preferences.

August 30, 2024
91 Articles